Steroidal pyrazolines evaluated as aromatase and quinone reductase-2 inhibitors for chemoprevention of cancer

被引：43
|
作者：
Abdalla, Mohamed M. [2 ]
Al-Omar, Mohamed A. [3 ]
Bhat, Mashooq A. [3 ]
Amr, Abdel-Galil E. [1 ,4 ]
Al-Mohizea, Abdullah M. [5 ]
机构：
[1] King Saud Univ, Coll Pharm, DEDC, Riyadh 11451, Saudi Arabia
[2] Saco Pharm Co, Res Unit, Cairo 11632, Egypt
[3] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, Riyadh 11451, Saudi Arabia
[4] Natl Res Ctr, Appl Organ Chem Dept, Cairo 12622, Egypt
[5] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11451, Saudi Arabia
来源：
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES | 2012年 / 50卷 / 04期
关键词：
Steroidal pyrazolines; Aromatase inhibitor; Quinone reductase-2 inhibitor; RECEPTOR MODULATORS SERMS; HETEROCYCLIC-COMPOUNDS; BREAST-CANCER; POTENTIAL ANTICANCER; DERIVATIVES; MELATONIN; ANALOGS;
D O I：
10.1016/j.ijbiomac.2012.02.006
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The aromatase and quinone reductase-2 inhibition of synthesized heterocyclic pyrazole derivatives fused with steroidal structure for chemoprevention of cancer is reported herein. All compounds were interestingly less toxic than the reference drug (Cyproterone (R)). The aromatase inhibitory activities of these compounds were much more potent than the lead compound resveratrol, which has an IC50 of 80 mu M. In addition, all the compounds displayed potent quinone reductase-2 inhibition. Initially the acute toxicity of the compounds was assayed via the determination of their LD50. The aromatase and quinone reductase-2 inhibitors resulting from this study have potential value in the treatment and prevention of cancer. Crown Copyright (C) 2012 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：1127 / 1132
页数：6
相关论文
共 50 条
  • [41] X-ray structural studies of quinone reductase 2 nanomolar range inhibitors
    Pegan, Scott D.
    Sturdy, Megan
    Ferry, Gilles
    Delagrange, Philippe
    Boutin, Jean A.
    Mesecar, Andrew D.
    PROTEIN SCIENCE, 2011, 20 (07) : 1182 - 1195
  • [42] Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
    Chen, Shanshan
    Bo, Lan
    Lv, Dan
    Ma, Fei
    BREAST CARE, 2022, 17 (04) : 391 - 402
  • [43] Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin
    Nazli Bahrami
    Shakila Jabeen
    Andliena Tahiri
    Torill Sauer
    Hilde Presterud Ødegård
    Stephanie Beate Geisler
    Berit Gravdehaug
    Laurens Cornelus Reitsma
    Knut Selsås
    Vessela Kristensen
    Jürgen Geisler
    Breast Cancer Research and Treatment, 2021, 190 : 435 - 449
  • [44] CHEMOPREVENTION FOR PROSTATE CANCER WITH 5-ALPHA-REDUCTASE INHIBITORS: WHAT ARE THE FULL RAMIFICATIONS ON ERECTILE FUNCTION?
    Pinsky, Michael
    Tracey, Anthony
    Gur, Serap
    Harbin, Andrew
    Hellstrom, Wayne
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 20 - 20
  • [45] Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin
    Bahrami, Nazli
    Jabeen, Shakila
    Tahiri, Andliena
    Sauer, Torill
    Odegard, Hilde Presterud
    Geisler, Stephanie Beate
    Gravdehaug, Berit
    Reitsma, Laurens Cornelus
    Selsas, Knut
    Kristensen, Vessela
    Geisler, Jurgen
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (03) : 435 - 449
  • [46] Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast cancer
    Wang, Min
    Gao, Mingzhang
    Miller, Kathy D.
    Sledge, George W.
    Hutchins, Gary D.
    Zheng, Qi-Huang
    STEROIDS, 2010, 75 (12) : 967 - 973
  • [47] Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer
    Chin, Y. S.
    Beresford, M. J.
    Ravichandran, D.
    Makris, A.
    BREAST, 2007, 16 (04): : 436 - 439
  • [48] Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 167 - 167
  • [49] Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors
    Adhikari, Nilanjan
    Baidya, Sandip Kumar
    Jha, Tarun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 208
  • [50] A Qualitative Systematic Review of the Evidence Base for Non-cross-resistance between Steroidal and Non-steroidal Aromatase Inhibitors in Metastatic Breast Cancer
    Beresford, M.
    Tumur, I.
    Chakrabarti, J.
    Barden, J.
    Rao, N.
    Makris, A.
    CLINICAL ONCOLOGY, 2011, 23 (03) : 209 - 215
12345